The United States Food and Drug Administration (FDA) has recently reported that a particular type of cancer has been linked to women with breast implants. The connection is being made between anaplastic large cell lymphoma (ALCL) and women who have received breast implants. Thus far the FDA has associated nine deaths to this form of cancer stemming from breast implants. In an official statement, the FDA reported that “All of the information to date suggests that women with breast implants have a very low but increased risk of developing ALCL compared to women who do not have breast implants”. Exact numbers are difficult to determine because ALCL is being linked to a very specific type of procedure but the FDA has revealed that they have received reports of 359 cases associated with ALCL and breast implants.
The FDA first discussed the potential risk associated between breast implants and developing cancer six years ago. However, at the time they did not have the technology to effectively research possible connections and draw any definitive solutions. Instead, the organization simply advised women who received implants to proceed with extra caution and regularly check with their doctor should they believe an abnormality occurred. However, recent research has revealed that there is a specific link between cancer and those who received “textured” breast implants. Of the cases, the FDA specifically analyzed almost 88 percent of the cancer victims also received texture breast implants. Fortunately, for those affected by the disease, the FDA reported that ALCL is a particularly slow-growing cancer and if caught in the early stages, it is typically treatable.